標(biāo)題: Titlebook: Handbook of Anticancer Pharmacokinetics and Pharmacodynamics; Michelle A. Rudek,Cindy H. Chau,Howard L. McLeod Book 2014Latest edition Spr [打印本頁(yè)] 作者: malcontented 時(shí)間: 2025-3-21 19:48
書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics影響因子(影響力)
書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics影響因子(影響力)學(xué)科排名
書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics網(wǎng)絡(luò)公開度
書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics被引頻次
書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics被引頻次學(xué)科排名
書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics年度引用
書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics年度引用學(xué)科排名
書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics讀者反饋
書目名稱Handbook of Anticancer Pharmacokinetics and Pharmacodynamics讀者反饋學(xué)科排名
作者: Directed 時(shí)間: 2025-3-22 00:00 作者: browbeat 時(shí)間: 2025-3-22 04:17
Phase 0 Trials in Oncology,gent demonstrates a desirable pharmacokinetic/pharmacodynamic profile, traditional phase I safety and tolerability studies are conducted; otherwise, further clinical development of the agent is unlikely to be justified. This chapter summarizes the key differences between phase 0 and phase I clinical作者: Inflamed 時(shí)間: 2025-3-22 06:34 作者: Traumatic-Grief 時(shí)間: 2025-3-22 10:46
Protein Binding,es in which monitoring of unbound concentrations might be useful: (1) agents demonstrating protein concentration-dependent binding, (2) agents that bind irreversible or near covalently, (3) when formulation excipients modulate unbound drug levels, and (4) metabolically interconversible agents. While作者: fertilizer 時(shí)間: 2025-3-22 15:58
Handbook of Anticancer Pharmacokinetics and Pharmacodynamics作者: Adherent 時(shí)間: 2025-3-22 17:11
The Vegetation and Physiography of Sumatraal and each has a role for specific drugs. However, no one method is a practical dose calculation strategy for many or all drugs. Neither body size nor fixed dosing alone can be used for currently available drugs. Conclusion: Dosing strategies for anticancer drugs should be individualized according 作者: 大溝 時(shí)間: 2025-3-22 23:20
https://doi.org/10.1007/978-94-015-8066-3gent demonstrates a desirable pharmacokinetic/pharmacodynamic profile, traditional phase I safety and tolerability studies are conducted; otherwise, further clinical development of the agent is unlikely to be justified. This chapter summarizes the key differences between phase 0 and phase I clinical作者: Goblet-Cells 時(shí)間: 2025-3-23 04:42 作者: HARP 時(shí)間: 2025-3-23 08:52 作者: Occipital-Lobe 時(shí)間: 2025-3-23 12:52
Book 2014Latest editiontherapy, high throughput platforms in drug metabolism and transport pharmacogenetics, imaging in drug development and nanotechnology in cancer..Authoritative and up-to-date, .Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, 2nd Edition. provides in one comprehensive and highly practical作者: crucial 時(shí)間: 2025-3-23 14:08
Natural Product Screening, these are modified for the screening of crude natural product extracts will be described. This chapter will also provide a summary of the importance of natural products to drug discovery and development, the results from screening assays developed, and the natural products isolated utilizing these screens.作者: nonradioactive 時(shí)間: 2025-3-23 18:32 作者: 樹膠 時(shí)間: 2025-3-23 22:58
Drug Interactions,ags that may occur between the administration of interacting drugs, the fact that some drugs can both induce and inhibit metabolism, and the inhibition of multiple pathways by some. The potential for drug–drug interaction needs to be considered in the development of new drugs as well as in the routine use of existing agents.作者: IRATE 時(shí)間: 2025-3-24 04:50 作者: Entrancing 時(shí)間: 2025-3-24 09:12
2196-9906 and new, additional chapters.Explores a wide variety of issu.There are many steps on the road from discovery of an anticancer drug to securing its final approval by the Food and Drug Administration. In this thoroughly updated and expanded second edition of the .Handbook of Anticancer Pharmacokinetic作者: Exploit 時(shí)間: 2025-3-24 13:48 作者: Pillory 時(shí)間: 2025-3-24 16:33
The Venture Capital Investment Process analysis is based on a mathematical model as a representation of the body to define model parameters by fitting the model to drug concentration–time data. This chapter serves to provide concepts and a set of guidelines for pharmacokinetic analysis using noncompartmental analysis and compartmental modeling approaches.作者: 枕墊 時(shí)間: 2025-3-24 20:51
https://doi.org/10.1057/9780230101944ags that may occur between the administration of interacting drugs, the fact that some drugs can both induce and inhibit metabolism, and the inhibition of multiple pathways by some. The potential for drug–drug interaction needs to be considered in the development of new drugs as well as in the routine use of existing agents.作者: 明確 時(shí)間: 2025-3-25 02:29 作者: 傳染 時(shí)間: 2025-3-25 03:57
Image & Seismic Information Processing,ials. This chapter summarizes the basic theory and application of pharmacometric techniques. Examples of where such pharmacometric principles have been successfully employed in oncology drug development are presented.作者: Vasoconstrictor 時(shí)間: 2025-3-25 10:21 作者: Perineum 時(shí)間: 2025-3-25 12:06
Donald E. Thomas,Philip R. Moorbyal to translating pharmacogenomics into clinical practice. This chapter highlights the advancements that have been made with key examples such as tamoxifen and CYP2D6, erlotinib and EGFR, vemurafenib and BRAF, and many others.作者: 青石板 時(shí)間: 2025-3-25 16:56
,Verilog — A Tutorial Introduction,ental factors appear to influence the CYP3A enzymatic activity more than genetic status. The challenges have been made to control the phenotypic CYP3A4 activity and to reduce pharmacokinetic variability of the relevant drugs. However, the clinical advantages obtained from these efforts should be carefully evaluated in view of clinical practice.作者: PANG 時(shí)間: 2025-3-25 20:52 作者: RAG 時(shí)間: 2025-3-26 00:33 作者: 美麗的寫 時(shí)間: 2025-3-26 06:27
Pharmacometrics,ials. This chapter summarizes the basic theory and application of pharmacometric techniques. Examples of where such pharmacometric principles have been successfully employed in oncology drug development are presented.作者: Tremor 時(shí)間: 2025-3-26 10:44 作者: exostosis 時(shí)間: 2025-3-26 14:51
Pharmacogenomics and Cancer Therapy: Somatic and Germline Polymorphisms,al to translating pharmacogenomics into clinical practice. This chapter highlights the advancements that have been made with key examples such as tamoxifen and CYP2D6, erlotinib and EGFR, vemurafenib and BRAF, and many others.作者: 發(fā)誓放棄 時(shí)間: 2025-3-26 20:42
Cytochrome P450,ental factors appear to influence the CYP3A enzymatic activity more than genetic status. The challenges have been made to control the phenotypic CYP3A4 activity and to reduce pharmacokinetic variability of the relevant drugs. However, the clinical advantages obtained from these efforts should be carefully evaluated in view of clinical practice.作者: 漂亮才會(huì)豪華 時(shí)間: 2025-3-26 22:24 作者: EWE 時(shí)間: 2025-3-27 04:01
Lower Extremity Occlusive Disease,DNA, microtubules, and nuclear hormone receptors. Novel targets are those under current preclinical and clinical investigation. The section on novel targets emphasizes the relationships of the novel targets to the biological traits of cancer.作者: 粗語(yǔ) 時(shí)間: 2025-3-27 07:08 作者: Progesterone 時(shí)間: 2025-3-27 11:18
Thorsten Botz-Bornstein,Noreen Abdullah-Khanation approaches, and endpoints. It will go on to examine the limitations of the current, widely accepted approaches and some of the problems facing investigators. Finally, it will also discuss how early anticancer drug development now faces a paradigm shift due to the advent of novel, molecularly targeted anticancer drugs.作者: venous-leak 時(shí)間: 2025-3-27 14:49
The Venture Capital Deformationthe intention to bridge the gap between clinical pharmacologists and subspecialty oncologists. This chapter showcases the rationale as to why the discipline of clinical pharmacology plays an increasingly significant role in clinical therapeutics (prescribing) in all specialties where drugs are used to treat disease.作者: Jingoism 時(shí)間: 2025-3-27 21:05 作者: 轉(zhuǎn)折點(diǎn) 時(shí)間: 2025-3-27 22:03
Molecular Targets,DNA, microtubules, and nuclear hormone receptors. Novel targets are those under current preclinical and clinical investigation. The section on novel targets emphasizes the relationships of the novel targets to the biological traits of cancer.作者: 法律 時(shí)間: 2025-3-28 04:14
Preclinical Screening for New Anticancer Agents,r nude mouse xenograft assays are also described. Examples of approved drugs that have been developed based on a particular screening approach and future perspectives for finding novel and more potent drugs are discussed.作者: nonchalance 時(shí)間: 2025-3-28 07:31 作者: 灰心喪氣 時(shí)間: 2025-3-28 12:48
Anticancer Clinical Pharmacology Overview,the intention to bridge the gap between clinical pharmacologists and subspecialty oncologists. This chapter showcases the rationale as to why the discipline of clinical pharmacology plays an increasingly significant role in clinical therapeutics (prescribing) in all specialties where drugs are used to treat disease.作者: 無(wú)價(jià)值 時(shí)間: 2025-3-28 14:52
Pharmacodynamic Modeling, study design optimized not only for the determination of clinical response and toxicity, but also for optimal measure of pharmacokinetic and pharmacodynamic measures. Pharmacodynamic models, study design, and pharmacodynamic biomarkers for anti-cancer clinical trials are discussed.作者: 呼吸 時(shí)間: 2025-3-28 21:34
,Verilog – A Tutorial Introduction,s a major role in the NER-pathway because of its damage recognition and excision ability. This chapter will review mechanisms of DNA repair and platinum resistance as it relates to the NER pathway and regulation of ERCC1. A brief discussion on the role of cancer stem cells in platinum resistance is also presented.作者: 口訣 時(shí)間: 2025-3-28 23:11
DNA Repair: ERCC1, Nucleotide Excision Repair, and Platinum Resistance,s a major role in the NER-pathway because of its damage recognition and excision ability. This chapter will review mechanisms of DNA repair and platinum resistance as it relates to the NER pathway and regulation of ERCC1. A brief discussion on the role of cancer stem cells in platinum resistance is also presented.作者: 脆弱吧 時(shí)間: 2025-3-29 06:49 作者: gout109 時(shí)間: 2025-3-29 08:39
Cancer Drug Discovery and Developmenthttp://image.papertrans.cn/h/image/420812.jpg作者: 學(xué)術(shù)討論會(huì) 時(shí)間: 2025-3-29 12:06
https://doi.org/10.1007/978-1-4614-9135-4Cancer; Pharmacodynamics; Pharmacogenetics; Pharmacokinetics; Pharmacology作者: Lumbar-Stenosis 時(shí)間: 2025-3-29 19:18 作者: alcohol-abuse 時(shí)間: 2025-3-29 22:17 作者: 刺耳的聲音 時(shí)間: 2025-3-30 03:55 作者: detach 時(shí)間: 2025-3-30 04:36 作者: OGLE 時(shí)間: 2025-3-30 10:20
https://doi.org/10.1007/978-1-349-20773-2cts as a source for new hits from which to develop new drugs will be discussed, and a brief overview of screening methods and techniques including how these are modified for the screening of crude natural product extracts will be described. This chapter will also provide a summary of the importance 作者: 窗簾等 時(shí)間: 2025-3-30 16:05 作者: 是限制 時(shí)間: 2025-3-30 18:25
https://doi.org/10.1007/978-94-015-8066-3ing toxicities in patients with cancer. Subsequent phase II and III trials evaluate whether the new agent has potential efficacy. This process is time consuming, expensive, involves potentially hundreds of patients, and has a high rate of failure. To address some of these limitations and facilitate 作者: Lipoprotein 時(shí)間: 2025-3-30 22:59
Thorsten Botz-Bornstein,Noreen Abdullah-Khanssible, and patients tend to have end-stage malignant processes, with many underlying symptoms and often organ dysfunction. This chapter will focus on the design of traditional early phase I clinical trials of anticancer therapies, including selection of patients, starting dose selection, dose-escal作者: 隱士 時(shí)間: 2025-3-31 03:57
Auguste Wackenheim,Jean Paul Braunroughout the drug development process, and numerous analytical assays are typically developed—from initial purification and assessment of impurities, to in vitro transport and metabolism studies, through large-scale pharmacokinetic studies to therapeutic drug monitoring. To ensure that data generate作者: MULTI 時(shí)間: 2025-3-31 06:21
Pressure Overload: Human Studies,icancer drug substances. Therefore, measurement of anticancer drug concentrations in biological matrices is an important aspect in the development of these products. Such data are required by regulating agencies to support new drug applications as well as for line extensions and generic products of 作者: Cardiac 時(shí)間: 2025-3-31 12:56 作者: GRILL 時(shí)間: 2025-3-31 16:40 作者: 高度表 時(shí)間: 2025-3-31 20:12 作者: Receive 時(shí)間: 2025-3-31 22:21 作者: 領(lǐng)先 時(shí)間: 2025-4-1 04:47 作者: 新奇 時(shí)間: 2025-4-1 09:22 作者: Canopy 時(shí)間: 2025-4-1 10:47
Donald E. Thomas,Philip R. Moorbys chapter focuses on the most up-to-date clinical trials involving pharmacogenomics and anticancer therapy. A brief introduction of drug development and the difference between somatic and germline DNA mutations sets up the chapter for understanding the progress which has been made in regard to indiv作者: FELON 時(shí)間: 2025-4-1 18:07 作者: CERE 時(shí)間: 2025-4-1 22:00 作者: Liberate 時(shí)間: 2025-4-2 00:16
,Verilog – A Tutorial Introduction,e excision repair (NER) pathway is the mammalian DNA repair mechanism that removes bulky DNA adducts induced by DNA damaging chemotherapeutic agents. Platinum compounds induce their cytotoxic effect by binding to a DNA molecule in the form of a platinum-DNA-adduct. The NER pathway is the main mechan
